NANOBIOTIX (NANO.PA) Fundamental Analysis & Valuation

EPA:NANO • FR0011341205

Current stock price

28.7 EUR
+0.55 (+1.95%)
Last:

This NANO.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NANO.PA Profitability Analysis

1.1 Basic Checks

  • In the past year NANO has reported negative net income.
  • NANO had a negative operating cash flow in the past year.
  • NANO had negative earnings in each of the past 5 years.
  • NANO had a negative operating cash flow in each of the past 5 years.
NANO.PA Yearly Net Income VS EBIT VS OCF VS FCFNANO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -114.32%, NANO is not doing good in the industry: 78.75% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NANO.PA Yearly ROA, ROE, ROICNANO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

  • NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NANO.PA Yearly Profit, Operating, Gross MarginsNANO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. NANO.PA Health Analysis

2.1 Basic Checks

  • NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NANO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NANO has been increased compared to 5 years ago.
  • NANO has a worse debt/assets ratio than last year.
NANO.PA Yearly Shares OutstandingNANO.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NANO.PA Yearly Total Debt VS Total AssetsNANO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -10.41, we must say that NANO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -10.41, NANO is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.41
ROIC/WACCN/A
WACC7.93%
NANO.PA Yearly LT Debt VS Equity VS FCFNANO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

  • A Current Ratio of 0.63 indicates that NANO may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.63, NANO is doing worse than 81.25% of the companies in the same industry.
  • NANO has a Quick Ratio of 0.63. This is a bad value and indicates that NANO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NANO has a worse Quick ratio (0.63) than 76.25% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
NANO.PA Yearly Current Assets VS Current LiabilitesNANO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. NANO.PA Growth Analysis

3.1 Past

  • The earnings per share for NANO have decreased strongly by -47.30% in the last year.
  • Looking at the last year, NANO shows a very negative growth in Revenue. The Revenue has decreased by -138.77% in the last year.
EPS 1Y (TTM)-47.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
Revenue 1Y (TTM)-138.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.77%

3.2 Future

  • Based on estimates for the next years, NANO will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.37% on average per year.
  • The Revenue is expected to grow by 19.96% on average over the next years. This is quite good.
EPS Next Y78.75%
EPS Next 2Y21.41%
EPS Next 3Y22.51%
EPS Next 5Y13.37%
Revenue Next Year103.37%
Revenue Next 2Y50.74%
Revenue Next 3Y31.26%
Revenue Next 5Y19.96%

3.3 Evolution

NANO.PA Yearly Revenue VS EstimatesNANO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 200M 400M 600M
NANO.PA Yearly EPS VS EstimatesNANO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. NANO.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • NANO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NANO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NANO.PA Price Earnings VS Forward Price EarningsNANO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NANO.PA Per share dataNANO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NANO's earnings are expected to grow with 22.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.41%
EPS Next 3Y22.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NANO.PA Dividend Analysis

5.1 Amount

  • NANO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NANO.PA Fundamentals: All Metrics, Ratios and Statistics

NANOBIOTIX

EPA:NANO (3/18/2026, 2:04:38 PM)

28.7

+0.55 (+1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)03-31
Inst Owners30.91%
Inst Owner ChangeN/A
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap1.39B
Revenue(TTM)-14.04M
Net Income(TTM)-51.64M
Analysts85
Price Target23.32 (-18.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)18.17%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)60.53%
EPS NY rev (3m)42.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)63.81%
Revenue NY rev (3m)40.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS-0.29
BVpS-1.42
TBVpS-1.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.5%
Cap/Sales -3.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -10.41
F-Score2
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)20.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
EPS Next Y78.75%
EPS Next 2Y21.41%
EPS Next 3Y22.51%
EPS Next 5Y13.37%
Revenue 1Y (TTM)-138.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.77%
Revenue Next Year103.37%
Revenue Next 2Y50.74%
Revenue Next 3Y31.26%
Revenue Next 5Y19.96%
EBIT growth 1Y-159.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year89.69%
EBIT Next 3Y28.42%
EBIT Next 5Y0.48%
FCF growth 1Y14.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.92%
OCF growth 3YN/A
OCF growth 5YN/A

NANOBIOTIX / NANO.PA Fundamental Analysis FAQ

What is the fundamental rating for NANO stock?

ChartMill assigns a fundamental rating of 1 / 10 to NANO.PA.


What is the valuation status for NANO stock?

ChartMill assigns a valuation rating of 1 / 10 to NANOBIOTIX (NANO.PA). This can be considered as Overvalued.


What is the profitability of NANO stock?

NANOBIOTIX (NANO.PA) has a profitability rating of 0 / 10.


Can you provide the financial health for NANO stock?

The financial health rating of NANOBIOTIX (NANO.PA) is 0 / 10.